文献速递冠心病

秋水仙碱在急性冠脉综合征患者中的应用:澳大利亚COPS随机临床试验

Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial.
PubMed 文献 · Circulation · 2020-08-29

COPS试验为多中心随机双盲安慰剂对照研究,纳入795例急性冠脉综合征患者,比较秋水仙碱(0.5mg每日两次用1月后改为每日一次用11月)与安慰剂。12个月随访时主要复合终点事件无显著差异(24 vs 38,P=0.09),但秋水仙碱组总死亡率更高(8 vs 1,P=0.017),尤其非心血管死亡(5 vs 0,P=0.024)。

要点

  • 秋水仙碱未显著改善ACS患者12个月主要复合心血管终点(P=0.09)。
  • 秋水仙碱组总死亡及非心血管死亡发生率显著高于安慰剂组。
  • 不良事件率两组无差异,以胃肠道症状为主。

核心结论

  • 在标准二级预防治疗基础上加用秋水仙碱未显著影响ACS患者12个月心血管结局,且与更高的死亡率相关。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,纳入澳大利亚17家医院795例成人ACS患者(18-85岁),冠脉造影证实冠心病并接受PCI或药物治疗。
  • 秋水仙碱组396例,安慰剂组399例;秋水仙碱剂量0.5mg每日两次用1个月,后0.5mg每日一次用11个月;随访至少12个月。

主要发现

  • 主要复合终点(全因死亡、ACS、缺血驱动的紧急血运重建、非心源性栓塞性缺血性卒中)12个月内秋水仙碱组24例 vs 安慰剂组38例(P=0.09,log-rank)。
  • 总死亡秋水仙碱组8例 vs 安慰剂组1例(P=0.017,log-rank);非心血管死亡5例 vs 0例(P=0.024,log-rank)。
  • 不良事件报告率秋水仙碱组23.0% vs 安慰剂组24.3%,以胃肠道症状为主(秋水仙碱23.0% vs 安慰剂20.8%)。

临床怎么用

  • 对于ACS患者,不推荐常规加用秋水仙碱以改善心血管预后,需警惕潜在死亡风险。

局限性

  • 原文摘要未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammation plays a crucial role in clinical manifestations and complications of acute coronary syndromes (ACS). Colchicine, a commonly used treatment for gout, has recently emerged as a novel therapeutic option in cardiovascular medicine owing to its anti-inflammatory properties. We sought to determine the potential usefulness of colchicine treatment in patients with ACS. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled trial involving 17 hospitals in Australia that provide acute cardiac care service. Eligible participants were adults (18-85 years) who presented with ACS and had evidence of coronary artery disease on coronary angiography managed with either percutaneous coronary intervention or medical therapy. Patients were assigned to receive either colchicine (0.5 mg twice daily for the first month, then 0.5 mg daily for 11 months) or placebo, in addition to standard secondary prevention pharmacotherapy, and were followed up for a minimum of 12 months. The primary outcome was a composite of all-cause mortality, ACS, ischemia-driven (unplanned) urgent revascularization, and noncardioembolic ischemic stroke in a time to event analysis. RESULTS: A total of 795 patients were recruited between December 2015 and September 2018 (mean age, 59.8±10.3 years; 21% female), with 396 assigned to the colchicine group and 399 to the placebo group. Over the 12-month follow-up, there were 24 events in the colchicine group compared with 38 events in the placebo group (P=0.09, log-rank). There was a higher rate of total death (8 versus 1; P=0.017, log-rank) and, in particular, noncardiovascular death in the colchicine group (5 versus 0; P=0.024, log-rank). The rates of reported adverse effects were not different (colchicine 23.0% versus placebo 24.3%), and they were predominantly gastrointestinal symptoms (colchicine, 23.0% versus placebo, 20.8%). CONCLUSIONS: The addition of colchicine to standard medical therapy did not significantly affect cardiovascular outcomes at 12 months in patients with ACS and was associated with a higher rate of mortality. Registration: URL: https://www.anzctr.org.au; Unique identifier: ACTRN12615000861550.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Tong DC, Quinn S, Nasis A, et al. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020. PMID: 32862667. doi:10.1161/CIRCULATIONAHA.120.050771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。